Sep 2026
24-Month Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV from the Italian BICSTaR Cohort.
B/F/TAF was well tolerated, with high levels of viral suppression and treatment persistence over 24 months, which were consistent with international real-world B/F/TAF data.
G. Marchetti, A. Antinori, V. Esposito et al.
· Current HIV Research · 0 citations